Situation: A nurse at the gynecology outpatient clinic of a provincial hospital cares for adult women with menstrual and menopausal problems. A 51-year-old woman had a hysterectomy for fibroids 6 years ago; both ovaries were left in place. She now has severe hot flashes and night sweats that disturb her sleep. She has no history of breast cancer, venous thromboembolism, stroke, heart disease, or liver disease. The physician plans menopausal hormone therapy (MHT). Which regimen should the nurse expect?

Two rules apply. Hot flashes and night sweats need systemic therapy, because low-dose vaginal estrogen treats only genitourinary symptoms. A progestogen is added to estrogen only to protect the endometrium in a woman with a uterus; after hysterectomy there is no endometrium to protect, so estrogen alone is used. Because she no longer menstruates, her menopause is recognized by her age and symptoms rather than by 12 months without a period.

Core clinical reasoning

A woman who has undergone hysterectomy with ovarian preservation still experiences menopausal symptoms because her ovaries continue to age and eventually decline in estrogen production. Her severe hot flashes and night sweats reflect systemic estrogen deficiency, not a localized vaginal problem. Therefore, the treatment target is systemic vasomotor symptom relief, which requires systemic estrogen.

After hysterectomy, the uterus is absent, so there is no endometrium to protect from estrogen-induced hyperplasia or malignancy; unopposed estrogen is therefore the expected regimen. Adding a progestogen would expose her to unnecessary progestogenic adverse effects without providing endometrial protection.

Why not the other options

Option	Rationale for exclusion
1. Progestogen alone daily	Progestogen does not reliably relieve hot flashes and is primarily used for endometrial protection in women with a uterus who take estrogen. In a hysterectomized woman, it adds risk without benefit.
2. Estrogen plus progestogen	Combined therapy is indicated only when the uterus is present. Without a uterus, the progestogen component is unnecessary and may increase breast cancer risk and cardiovascular risk compared with estrogen alone.
3. Low-dose vaginal estrogen alone	Vaginal estrogen is designed for genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms). It does not achieve systemic levels sufficient to control vasomotor symptoms such as hot flashes and night sweats.
4. Estrogen alone daily	Correct. Systemic estrogen is the standard for vasomotor symptoms in a woman without a uterus.

Pathophysiology and clinical application

Hot flashes arise from narrowing of the thermoneutral zone in the hypothalamus when estrogen levels fall. Systemic estrogen restores central thermoregulatory stability. Because this patient’s symptoms are severe enough to disturb sleep, local vaginal therapy would be inadequate.

Key point! The decision to add a progestogen depends on the presence of a uterus, not on whether menopause is natural or surgical. This patient had a hysterectomy 6 years ago, so the uterus is absent regardless of ovarian status.

Estrogen-only therapy after hysterectomy is supported by evidence showing a lower breast cancer risk compared with placebo in hysterectomized women. A meta-analysis of 10 randomized trials found that 3.6% of women randomized to estrogen alone developed breast cancer versus 4.7% of those on placebo (relative risk 0.77, 95% CI 0.65–0.91) ^[3]. This safety profile further supports avoiding unnecessary progestogen exposure.

Assessment cues in this patient

Her age (51 years) and symptom pattern are consistent with natural menopause despite the absence of menses. Because hysterectomy removes the menstrual marker, menopause is identified clinically by age, vasomotor symptoms, and sometimes laboratory confirmation of elevated FSH with low estradiol. The absence of contraindications—no history of breast cancer, venous thromboembolism, stroke, heart disease, or liver disease—makes her a suitable candidate for systemic estrogen therapy ^[1].

Watch out! If this patient still had a uterus, estrogen alone would be contraindicated due to the risk of endometrial hyperplasia and cancer. The hysterectomy changes the entire risk–benefit calculation.

Pharmacokinetic considerations

Systemic estrogen can be delivered by oral, transdermal, or subcutaneous routes. A study of a 25 mg subcutaneous estradiol implant in hysterectomized women demonstrated sustained systemic estradiol delivery and symptom improvement, confirming that estrogen-only formulations are appropriate for this population . The route of administration does not change the fundamental principle that progestogen is unnecessary after hysterectomy.